PT-112 Demonstrates Promising Efficacy in Recurrent Thymoma Phase 2 Trial
核心洞察
Promontory Therapeutics (搜索)' PT-112 achieved a 30% objective response rate in recurrent thymoma (搜索) patients, exceeding the interim efficacy requirement for the Phase 2 study.
Three of the first 10 patients evaluated showed RECIST partial responses, surpassing the protocol requirement of two responses among the first 16 patients.
The drug demonstrated immune activation across adaptive and innate immune systems while maintaining a favorable safety profile with no treatment discontinuations due to adverse events.
Promontory Therapeutics (搜索) announced that its investigational small molecule PT-112 has exceeded the pre-specified interim efficacy requirement in a Phase 2 study for recurrent thymoma (搜索), a rare cancer with no approved treatments. The clinical milestone represents a significant development for patients facing limited therapeutic options in this orphan indication.
Clinical Efficacy Results
Of the first ten patients with thymoma (搜索) assessed for tumor response in the ongoing Phase 2 clinical trial at the National Cancer Institute (NCI), three patients (30%) experienced RECIST partial responses. This objective response rate numerically exceeds recent Phase 2 monotherapy data in the public domain with current off-label treatment options for this indication.
The efficacy findings surpassed the protocol's interim requirement of two responses among the first 16 patients evaluated to proceed with stage 2 of efficacy assessment. Following this milestone, enrollment continues at the NCI under a formal Collaborative Research and Development Agreement (CRADA) with Promontory Therapeutics (搜索).
Safety and Tolerability Profile
PT-112 demonstrated a favorable safety profile in the study population. Patients treated with a dosing regimen based upon the PT-112 recommended Phase 3 dose (RP3D) achieved durable disease control without symptomatic toxicities. Notably, no discontinuations due to adverse events occurred during the treatment period.
The RP3D was previously agreed with the FDA at a recent end of Phase 2 meeting on the separate PT-112 program in metastatic castration-resistant prostate cancer (搜索), providing regulatory validation for the dosing approach.
Immune System Activation
Recent immuno-profiling findings presented by NCI investigators at the American Association of Cancer Research (AACR) 2025 Annual Meeting demonstrated PT-112's mechanism of action. Among the first 15 thymic epithelial tumor (搜索) patients treated with PT-112 monotherapy, increases in both adaptive (CD8+ and CD4+) and innate (NK) cell types reached statistical significance.
The investigators concluded that "PT-112 induces robust signals of immune activation across the adaptive and innate immune systems indicative that PT-112's immune effects play a significant role in its anti-cancer mechanism." Consistent with these findings, recent on-treatment biopsies showed increased CD8+ T cell infiltration in tumor tissue and absence of viable tumor in two participants with stable disease per RECIST.
Addressing Unmet Medical Need
Patients with recurrent thymoma (搜索) face significant treatment challenges, with limited options for standard of care treatment and no drug approved for this indication in the United States, European Union, or Japan. The disease presents additional complexity as patients with thymoma are at risk for paraneoplastic autoimmune diseases, which increases the risk of immune-related adverse events with T cell-directed immunotherapy.
Early observations indicate an absence of increased incidence of new-onset immune-related adverse events in patients with thymoma (搜索) receiving PT-112, coupled with evidence of clinical and immune activity. This profile provides a unique opportunity to offer a novel immunomodulatory treatment that does not increase the risk of immune toxicity.
Development Plans
Promontory Therapeutics (搜索) is planning the next stage of development of PT-112 in recurrent thymoma (搜索). The company leadership will participate in industry partnering meetings during the JPMorgan Healthcare conference week in San Francisco, beginning January 12th, to advance the program's development strategy.